ERBB2 and neoplasm: The similarity between the immune composition of different tumor molecular subtypes supports the putative contribution of TI-NK cells to the clinical efficacy of treatments such as chemotherapy and immunotherapy in triple negative breast cancer or to the recently approved antibody–drug conjugates for HER2-positive tumors.